Lorne Golub, DMD, MSc, MDSc (Hon), DSc

Peer Reviewed Journals

Golub LM, Stern B, Glimcher M and Goldhaber P: The effect of a lathyrogenic agent on the synthesis and degradation of mouse bone collagen in tissue culture. Archs. Oral Biol., 13:1395–1398, 1968.

Golub LM, Glimcher M and Goldhaber P: The effect of sodium fluoride on the rates of synthesis and degradation of bone collagen in tissue culture. Proc. Soc. Exptl. Biol. Med., 129:973–977, 1968.

Shimizu M, Golub LM and Goldhaber P: The effect of lathyrogens on the rate of collagen fibril formation and dissolution. Biochim. Biophys. Acta, 168:356–358, 1968.

Golub LM, Stern B, Glimcher M and Goldhaber P: The inhibition of the maturation of newly synthesized bone collagen by β‑aminopropionitrile in tissue culture. Proc. Soc. Exptl. Biol. Med., 129:465–469, 1968.

Haddad R, Golub LM, Gedalia I and Goldhaber P: The effect of fluoride on carbohydrate metabolism of bone in tissue culture. J. Dent. Res., 49:639–640, 1970.

Stern B, Golub LM and Goldhaber P: Effects of demineralization and parathyroid hormone on the availability and susceptibility of bone collagen to degradation by collagenase. J. Periodontol. Res., 5:116–121, 1970.

Golub LM and Chow K: The effect of fluoride and ascorbic acid on bone growth in tissue culture. J. Periodontol. Res., 6:73–79, 1971.

Golub LM, Borden SM and Kleinberg I: Urea content of gingival crevicular fluid and its relation to periodontal disease in humans. J. Periodont. Res., 6:243–251, 1971.

Golub LM: The effect of ascorbic acid on the turnover and solubility of bone collagen in tissue culture. J. Periodont. Res., 8:71–78, 1973.

Ramamurthy NS, Zebrowski EJ and Golub LM: Collagenolytic activity of alloxan diabetic rat gingivae. Diabetes, 22:272–274, 1973.

Golub LM, Stakiw JE and Singer DL: Collagenolytic activity of human gingival crevice fluid. J. Dent. Res., 53(6):1501, 1974.

Golub LM and Kleinberg I: Gingival crevicular fluid: A new diagnostic aid in managing the periodontal patient. Oral Sci. Revs., 8:49–61, 1976.

Golub LM, Siegal K, Ramamurthy NS and Mandel I: Some characteristics of collagenase activity in gingival crevicular fluid and its relationship to gingival disease in humans. J. Dent. Res., 55:1049–1057, 1976.

Golub LM, Kennett S, McEwan H, Curran JB and Ramamurthy NS: Collagenolytic activity of crevicular fluid from pericoronal gingival flaps. J. Dent. Res., 55(2):177–181, 1976.

Borden SM, Golub LM and Kleinberg I: The effect of age and sex on the relationship between crevicular fluid flow and gingival inflammation in humans. J. Periodontal Res., 12:160–165, 1977.

Golub LM, Garant PR and Ramamurthy NS: Inflammatory changes in gingival collagen in the alloxan‑diabetic rat. J. Periodontal Res., 12:402–418, 1977.

Ciancio SG, Golub LM, Mosovich L, Katz C and Kleinberg I: Urea levels in the gingival crevices of diabetic and normal adolescents. J. Dent Res., 56(10):1144, 1977.

Golub LM, Greenwald RA, Zebrowski EJ and Ramamurthy NS: The effect of experimental diabetes on the molecular characteristics of rat tail tendon collagen. Biochim. Biophys. Acta, 534:73–81, 1978.

Golub LM, Schneir M and Ramamurthy NS: Enhanced collagenase activity in diabetic rat gingiva: In vitro and in vivo evidence. J. Dent Res., 57(3):520–525, 1978.

Golub LM, Kaplan R, Mulvihill JE and Ramamurthy NS: Collagenolytic activity of crevicular fluid and of adjacent gingival tissue. J. Dent Res., 58(11):2132–2136, 1979.

Nicoll GA, Gollapudi GM, Ramamurthy NS and Golub LM: Suppressed collagenolytic activity in polymorphonuclear leukocytes from diabetic humans. Experientia, 37:315–317, 1981.

Golub LM, Iacono VJ, Nicoll GA, Ramamurthy NS and Kaslick RS: The response of human sulcular leukocytes to a chemotactic challenge: A new in vivo assay. J. Periodont. Res., 16:171–179, 1981.

Golub LM, Nicoll GA, Iacono VJ and Ramamurthy NS: In vivo crevicular leukocyte response to a chemotactic challenge: Inhibition by experimental diabetes. Infect. Immun., 37:1013–1020, 1982.

Ramamurthy NS and Golub LM: Diabetes increases collagenase activity in extracts of rat gingiva and skin. J. Periodontal Res., 18(1):23–30, 1983.

Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R and Ramamurthy NS: Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. J. Periodont. Res., 18:516–526, 1983.

Golub LM and Kleinberg I: Gingival crevicular fluid: A new diagnostic aid in managing the periodontal patient. Oral Sci. Revs., 8:49–61, 1976.

Golub LM, Siegal K, Ramamurthy NS and Mandel I: Some characteristics of collagenase activity in gingival crevicular fluid and its relationship to gingival disease in humans. J. Dent. Res., 55:1049–1057, 1976.

Golub LM, Kennett S, McEwan H, Curran JB and Ramamurthy NS: Collagenolytic activity of crevicular fluid from pericoronal gingival flaps. J. Dent. Res., 55(2):177–181, 1976.

Borden SM, Golub LM and Kleinberg I: The effect of age and sex on the relationship between crevicular fluid flow and gingival inflammation in humans. J. Periodontal Res., 12:160–165, 1977.

Golub LM, Garant PR and Ramamurthy NS: Inflammatory changes in gingival collagen in the alloxan-diabetic rat. J. Periodontal Res., 12:402–418, 1977.

Ciancio SG, Golub LM, Mosovich L, Katz C and Kleinberg I: Urea levels in the gingival crevices of diabetic and normal adolescents. J. Dent. Res., 56(10):1144, 1977.

Golub LM, Greenwald RA, Zebrowski EJ and Ramamurthy NS: The effect of experimental diabetes on the molecular characteristics of rat tail tendon collagen. Biochim. Biophys. Acta, 534:73–81, 1978.

Golub LM, Schneir M and Ramamurthy NS: Enhanced collagenase activity in diabetic rat gingiva: In vitro and in vivo evidence. J. Dent. Res., 57(3):520–525, 1978.

Golub LM, Kaplan R, Mulvihill JE and Ramamurthy NS: Collagenolytic activity of crevicular fluid and of adjacent gingival tissue. J. Dent. Res., 58(11):2132–2136, 1979.

Nicoll GA, Gollapudi GM, Ramamurthy NS and Golub LM: Suppressed collagenolytic activity in polymorphonuclear leukocytes from diabetic humans. Experientia, 37:315–317, 1981.

Golub LM, Iacono VJ, Nicoll GA, Ramamurthy NS and Kaslick RS: The response of human sulcular leukocytes to a chemotactic challenge: A new in vivo assay. J. Periodont. Res., 16:171–179, 1981.

Golub LM, Nicoll GA, Iacono VJ and Ramamurthy NS: In vivo crevicular leukocyte response to a chemotactic challenge: Inhibition by experimental diabetes. Infect. Immun., 37:1013–1020, 1982.

Ramamurthy NS and Golub LM: Diabetes increases collagenase activity in extracts of rat gingiva and skin. J. Periodontal Res., 18(1):23–30, 1983.

Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R and Ramamurthy NS: Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. J. Periodont. Res., 18:516–526, 1983.

From the National Institutes of Health: Tetracyclines block collagenase activity. JAMA, 252(15), 1984.

Gomes BC, Golub LM and Ramamurthy NS: Tetracyclines inhibit parathyroid hormone-induced bone resorption in organ culture. Experientia, 40:1273–1275, 1984.

Golub LM, Evans RT, McNamara TF, Lee HM and Ramamurthy NS: A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann. N.Y. Acad. Sci., 732:96–111, 1984.

Golub LM, Ramamurthy NS, McNamara TF, Gomes BC, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S, Schneir M and Perry H: Tetracyclines inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease. J. Periodont. Res., 19:651–655, 1984.

Golub LM, Wolff MS, Lee HM, McNamara TF, Ryan ME and Ramamurthy NS: Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J. Periodont. Res., 20:12–23, 1985.

Golub LM, Goodson JM, Lee HM, Vidal AM, McNamara TF, Weiner MS and Ramamurthy NS: Locally and low-dose systemically administered tetracyclines inhibit tissue collagenase activity: Potential new approaches in the treatment of periodontal disease. J. Periodontol., 56(Special issue):93–97, 1985.

Zucker S, Lysik RM, Ramamurthy NS, Golub LM, Tschesche H and Delaney P: Diversity of plasma membrane proteinases in mouse melanoma cells: Inhibition of collagenolytic and cytolytic activity by minocycline. J. Nat. Cancer Inst., 75:517–525, 1985.

Perry H and Golub LM: Systemic tetracyclines in the treatment of non-infected corneal ulcers. Ann. Ophthalmol., 17:742–744, 1985.

Schneir M, Ramamurthy NS and Golub LM: Dietary ascorbic acid normalized diabetes-induced underhydroxylation of nascent type I collagen molecules. Collagen Rel. Res., 5:415–422, 1985.

Perry DP, Kenyon KR, Lamberts DW, Foulks GN, Seedor JA and Golub LM: Systemic tetracycline hydrochloride as adjunctive therapy in the treatment of persistent epithelial defects. Ophthalmology, 93:1320–1322, 1986.

Leung MK, Folkes GA, Ramamurthy NS and Golub LM: Diabetes stimulates procollagen degradation in rat tendon in vitro. Biochim. Biophys. Acta, 880:147–152, 1986.

Seedor JA, Perry HD, McNamara TF, Golub LM, Buxton DF and Guthrie DS: Systemic tetracycline treatment of alkali‑induced corneal ulceration in rabbits. Arch. Ophthalmol., 105:268–271, 1987.

Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Zucker S and Tschesche H: Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J. Rheumatol., 14:28–32, 1987.

Golub LM, McNamara TF, D’Angelo G, Greenwald RA and Ramamurthy NS: A non‑antimicrobial chemically‑modified tetracycline inhibits mammalian collagenase activity. J. Dent. Res., 66:1310–1314, 1987.

Schneir M, Imberman M, Ramamurthy NS and Golub LM: Streptozotocin‑induced diabetes and the rat periodontium: Decreased relative collagen production. Collagen Rel. Res., 8:221–232, 1988.

Zucker S, Wieman JM, Lysik RM, Imhof B, Nagase H, Ramamurthy NS and Golub LM: Gelatin‑degrading type IV collagenase isolated from human small cell lung cancer. Invasion Metastasis, 9:167–181, 1989.

Schneir M, Ramamurthy NS and Golub LM: Minocycline treatment of diabetic rats increases skin collagen production and mass. Matrix, 10:112–123, 1990.

Golub LM, Ramamurthy NS and Rifkin BR: Tetracycline administration prevents diabetes‑induced osteopenia in the rat. Res. Commun. Chem. Path. Pharmacol., 68:27–40, 1990.

Golub LM: Reduction with tetracyclines of excessive collagen degradation in periodontal and other diseases. N.Y. St. Dent. J., 56:24–26, 1990.

Kaneko H, Sasaki T, Ramamurthy NS and Golub LM: Tetracycline administration normalizes osteoclast structure and acid phosphatase activity in diabetic rats. Anat. Rec., 227:427–436, 1990.

Golub LM, Ciancio S, Ramamurthy NS, Leung M and McNamara TF: Low‑dose doxycycline therapy: Effect on gingival and crevicular fluid collagenase activity in humans. J. Periodont. Res., 25:321–330, 1990.

Sasaki T, Ramamurthy NS and Golub LM: Insulin‑deficient diabetes impairs osteoblast and periodontal ligament fibroblast metabolism. J. Biol. Buccale, 18:215–226, 1990.

Ramamurthy NS, Vernillo AT, Golub LM and Rifkin BR: The effect of tetracyclines on collagenase activity in rat osteoblastic cells. Res. Commun. Chem. Path. Pharmacol., 70:323–335, 1990.

Klausen B, Evans RT, Ramamurthy NS, Golub LM, Lee YJ, Zambon JJ and Genco RJ: Reduced periodontal bone loss in rats immunized with Bacteroides gingivalis. Oral Microbiol. Immunol., 6:193–201, 1991.

Golub LM, Greenwald RA, Ramamurthy NS, McNamara TF and Rifkin BR: Tetracyclines inhibit connective tissue breakdown. Crit. Revs Oral Biol. Med., 2:297–322, 1991.

Sasaki T, Kaneko H, Ramamurthy NS and Golub LM: Tetracycline administration restores osteoblast structure during diabetes. Anat. Rec., 231:25–34, 1991.

Sorsa T, Ingman T, Mikkinen T, Suomalaien K, Golub LM and Thesleff I: Characterization of collagenase during orthodontic tooth movement. Biol. Mech. Tooth Move. Craniofac. Adapt., 47–51, 1992.

Suomalainen K, Sorsa T, Ingman T, Lindy O and Golub LM: Tetracycline‑inhibition identifies cellular origin of collagenases in periodontal disease. Oral Microbiol. Immunol., 7:121–123, 1992.

Lauhio A, Sorsa T, Lindy O, Suomalainen K, Golub LM and Konttinen YT: Anticollagenolytic potential of lymecycline. Arth. Rheumat., 35:195–198, 1992.

Greenwald RA, Moak SA, Ramamurthy NS and Golub LM: Tetracyclines suppress metalloproteinase activity in arthritis. J. Rheumatol., 19:927–938, 1992.

Evans RT, Klausen B, Ramamurthy NS, Golub LM and Genco RJ: Periodontopathic potential of Porphyromonas gingivalis strains. Archs Oral Biol., 37:813–819, 1992.

Golub LM, Suomalainen K and Sorsa T: Host modulation with tetracyclines. Curr. Opin. Dent., 2:80–90, 1992.

Golub LM, Greenwald RA, Ramamurthy NS, Zucker S and Tschesche H: Tetracyclines inhibit matrix metalloproteinases. Matrix, Suppl. 1:315–316, 1992.

Sorsa T, Ingman T, Suomalainen K, Halinen S, Konttinen YT, Uitto VJ and Golub LM: Cellular source of collagenase in diabetes. J. Clin. Periodontol., 19:146–149, 1992.

Sorsa T, Konttinen YT, Lindy O, Suomalainen K, Ingman T, Saari H, Halinen S, Lee HM, Golub LM, Hall J and Simon S: Doxycycline protects serum alpha‑1‑antitrypsin from human neutrophil collagenase. Joint Destr. Arth. Osteoarthritis, 39:225–229, 1993.

Ingman T, Sorsa T, Suomalainen K, Halinen S, Lindy O, Lauhio A, Konttinen YT and Golub LM: Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. J. Periodontol., 64:82–88, 1993.

Rifkin BR, Vernillo AT and Golub LM: Blocking periodontal disease progression by inhibiting tissue‑destructive enzymes. J. Periodontol., 64(Supplement):819–827, 1993.

Ramamurthy NS, Vernillo AT, Greenwald RA, Lee HM, Sorsa T, Golub LM and Rifkin BR: Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J. Bone Min. Res., 8:1247–1253, 1993.

Yu Z, Ramamurthy NS, Leung M, Chang KM, McNamara TF and Golub LM: Chemically modified tetracycline normalizes collagen metabolism in diabetic rats. J. Periodontal Res., 28:420–428, 1993.

Sorsa T, Lindy O, Konttinen YT, Suomalainen K, Ingman T, Saari H, Halinen S, Lee HM, Golub LM, Hall J and Simon S: Doxycycline protects serum alpha‑1‑antitrypsin from neutrophil collagenase. Antimicrob. Agents Chemotherap., 37:592–594, 1993.

Lauhio A, Nordstrom D, Sorsa T, Saari H, Rose S, Lindy O, Golub LM and Konttinen YT: Long‑term tetracycline treatment of reactive arthritis. Prog. Rheumatol., 5:84–89, 1993.

Lauhio A, Konttinen YT, Tschesche H, Nordstrom D, Salo T, Landevirta J, Golub LM and Sorsa T: Reduction of matrix metalloproteinase‑8 levels during doxycycline treatment. Antimicrob. Agents Chemotherap., 38:400–402, 1993.

Perry HD, Hodes LW, Seedor JA, Donnenfeld ED, McNamara TF and Golub LM: Effect of doxycycline hyclate on corneal wound healing. Cornea, 12:379–382, 1993.

Nip LH, Uitto VJ and Golub LM: Inhibition of epithelial cell matrix metalloproteinases by tetracyclines. J. Periodontal Res., 28:379–385, 1993.

Golub LM, Wolff M, Roberts S, Lee HM, Leung M and Payonk GS: Treating periodontal diseases by blocking tissue‑destructive enzymes. J. Amer. Dent. Assoc., 125:163–169, 1994.

Ramamurthy NS, Leung M, Moak S, Greenwald RA and Golub LM: CMT/NSAID combination increases bone uptake. Annal. N.Y. Acad. Sci., 696:420–421, 1994.

Vernillo AT, Ramamurthy NS, Golub LM and Rifkin BR: Non‑antimicrobial properties of tetracycline. Curr. Opin. Periodont., 2:111–118, 1994.

Sasaki T, Ramamurthy NS and Golub LM: Bone cells bind chemically modified tetracycline. Bone, 15:373–375, 1994.

Golub LM, Evans RT, McNamara TF, Lee HM and Ramamurthy NS: Non‑antimicrobial tetracycline inhibits gingival metalloproteinases. Ann. N.Y. Acad. Sci., 732:96–111, 1994.

Rifkin BR, Vernillo AT, Ramamurthy NS and Golub LM: Modulation of bone resorption by tetracyclines. Annal. N.Y. Acad. Sci., 732:165–180, 1994.

Greenwald RA, Moak SA and Golub LM: Low‑dose doxycycline inhibits pyridinoline excretion. Annal. N.Y. Acad. Sci., 732:419–421, 1994.

Karimbux NY, Ramamurthy NS, Golub LM and Nishimura I: Tissue healing with doxycycline. Ann. N.Y. Acad. Sci., 732:433–435, 1994.

Lauhio A, Konttinen YT, Salo T, Nordstrom D, Golub LM and Sorsa T: In vivo doxycycline effects on metalloproteinases. Ann. N.Y. Acad. Sci., 732:431–432, 1994.

Mallya SK, Hall JE, Lee HM, Rolmes EJ, Simon SR and Golub LM: Metalloproteinase interactions with inhibitors. Ann. N.Y. Acad. Sci., 732:303–314, 1994.

Uitto VJ, Firth JD, Nip L and Golub LM: Doxycycline inhibits gelatinase gene expression. Annal. N.Y. Acad. Sci., 732:140–151, 1994.

Chang KM, Ramamurthy NS, McNamara TF, Evans RT, Klausen B, Murray PA and Golub LM: Tetracyclines inhibit alveolar bone loss. J. Periodontal Res., 29:242–249, 1994.

Sorsa T, Mantyla P, Ronka H, Kallio P, Kinane D, Salo T and Golub LM: Scientific basis of matrix metalloproteinase‑8 testing. Ann. N.Y. Acad. Sci., 878:130–140, 1999.

Golub LM, Ramamurthy NS, Llavaneras A, Ryan ME, Lee HM, Liu Y, Bain S and Sorsa T: Chemically modified tetracycline inhibits periodontal breakdown. Ann. N.Y. Acad. Sci., 878:290–310, 1999.

Ryan ME, Ramamurthy NS, Sorsa T and Golub LM: Matrix metalloproteinase‑mediated events in diabetes. Ann. N.Y. Acad. Sci., 878:311–334, 1999.

Sasaki T, Ohyori N, Debari K, Ramamurthy NS and Golub LM: Effects of chemically‑modified tetracyclines on bone loss and osteoclast structure in osteoporotic states. Ann. N.Y. Acad. Sci., 878:347–360, 1999.

Kirkwood KL, Golub LM and Bradford PG: Non‑antimicrobial and antimicrobial tetracyclines inhibit interleukin‑6 expression in murine osteoblasts. Ann. N.Y. Acad. Sci., 878:667–670, 1999.

Llavaneras S, Golub LM, Rifkin BR, Heikkila P, Teronen O, Salo T, Ryan ME and Sorsa T: CMT‑8 and clodronate synergistically inhibit alveolar bone loss. Ann. N.Y. Acad. Sci., 878:671–674, 1999.

Golub LM, Greenwald RA and Thompson RW: Tetracycline use and risk of acute myocardial infarction. JAMA, 282:1997–1998, 1999.

Ramamurthy NS, McClain SA, Pirila E, Maisi P, Salo T, Kucine A, Sorsa T, Vishram F and Golub LM: Wound healing in aged rats treated with chemically modified doxycycline. Ann. N.Y. Acad. Sci., 878:720–723, 1999.

Carney DE, Lutz CJ, Picone A, Gatto LA, Ramamurthy NS, Golub LM, Simon SR, Searles B, Paskanik A, Schmeide K, Finck C, Shidttle HJ and Nierman GS: Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation, 100:400–406, 1999.

Lukkonen A, Sorsa T, Salo T, Koivunen E, Golub LM, Simon SR and Stenman UH: Down‑regulation of trypsinogen‑2 by chemically‑modified tetracyclines. Int. J. Cancer, 86:577–581, 2000.

Ryan ME and Golub LM: Modulation of matrix metalloproteinase activities in periodontitis. Periodontology 2000, 24:226–238, 2001.

Greenwald RA and Golub LM: Biologic properties of non‑antibiotic chemically‑modified tetracyclines. Curr. Med. Chem., 8:237–242, 2001.

Golub LM, McNamara TF, Ryan ME, Kohut B, Blieden T, Payonk G, Sipos T and Baron HJ: Adjunctive treatment with sub‑antimicrobial doxycycline in adult periodontitis. J. Clin. Periodontol., 28:146–156, 2001.

Liu Y, Ramamurthy NS, Maracek J, Lee HM, Ryan ME, Rifkin BR and Golub LM: Lipophilicity and cellular uptake of chemically modified tetracyclines. Curr. Med. Chem., 8:243–252, 2001.

Chen JL, Bookbinder M, Ryan ME, Golub LM, Ashley R and Ramamurthy NS: Biodistribution of radiolabeled CMT‑3 in rats. Curr. Med. Chem., 8:253–256, 2001.

Lee HM, Golub LM, Cao J, Teronen O, Salo T, Zucker S and Sorsa T: Non‑antimicrobial tetracycline inhibits MT1‑MMP activity. Curr. Med. Chem., 8:257–260, 2001.

Gu Y, Lee HM, Roemer EJ, Golub LM and Simon SR: Inhibition of tumor cell invasiveness by chemically modified tetracycline. Curr. Med. Chem., 8:261–270, 2001.

Pirila E, Ramamurthy NS, McClain S, Kucine A, Golub LM, Salo T and Sorsa T: Wound healing in ovariectomized rats treated with CMT‑8. Curr. Med. Chem., 8:281–294, 2001.

Ramamurthy NS, Bain S, Liang CT, Banes J and Golub LM: Combination therapy inhibits bone loss in ovariectomized rats. Curr. Med. Chem., 8:295–304, 2001.

Ryan ME, Usman A, Ramamurthy NS, Golub LM and Greenwald RA: Excessive matrix metalloproteinase activity in diabetes. Curr. Med. Chem., 8:305–316, 2001.

Llavaneras A, Ramamurthy NS, Heikkila P, Teronen O, Salo T, Rifkin BR, Ryan ME, Golub LM and Sorsa T: Combination therapy inhibits endotoxin‑induced periodontal breakdown. J. Periodontol., 72:1069–1077, 2001.

Grenier D, Plamondon P, Sorsa T, Lee HM, Golub LM, Teronen O and Mayrand D: Inhibition of proteolytic activities by doxycycline and chemically modified tetracyclines. J. Periodontol., 73:19–28, 2002.

Liu Y, Tortora G, Ryan ME, Lee HM and Golub LM: Phosphate effects on antifungal activity of CMT‑3. Antimicrob. Agents Chemother., 46:1455–1461, 2002.

Liu Y, Ryan ME, Lee HM, Simon SR, Tortora G, Leung M and Golub LM: A chemically modified tetracycline is a new antifungal agent. Antimicrob. Agents Chemother., 46:1447–1454, 2002.

Pirila E, Ramamurthy NS, McClain S, Kucine A, Golub LM, Salo T and Sorsa T: Chemically modified tetracycline and estrogen promote wound healing in ovariectomized rats. Wound Rep. Reg., 10:38–51, 2002.

Lokeshwar BL, Selzer MG, Zhu B, Block NL and Golub LM: Inhibition of cell proliferation, invasion and metastasis by a non‑antimicrobial tetracycline analogue. Int. J. Cancer, 98:297–309, 2002.

Ramamurthy NS, Rifkin BR, Greenwald RA, Liu Y, Turner G, Golub LM and Vernillo AT: Inhibition of matrix metalloproteinase‑mediated periodontal bone loss by chemically modified tetracyclines. J. Periodontol., 73:726–734, 2002.

Brown DL, Desai K, Vakili BA, Chadi N, Lee HM and Golub LM: Clinical and biochemical results of metalloproteinase inhibition to prevent acute coronary syndromes. Circulation, 106(Suppl.):II‑455, 2002.

Ramamurthy NS, Pirila E, Lee HM, Maisi P, McClain S, Kucine A, Wahlgren J, Salo T, Wolff M, Sorsa T and Golub LM: Delayed wound healing in ovariectomized rats normalized by estrogen or chemically modified doxycycline. Menopause, 2003.

Golub LM, Brown DL, Desai K, Lee HM and Ryan ME: Sub‑antimicrobial doxycycline reduces biomarkers of inflammation in acute coronary syndromes. Inflam. Res., 52(Suppl. 2):S157, 2003.

Lee HM, Ciancio SG, Tuter G, Ryan ME and Golub LM: Sub‑antimicrobial doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis. J. Periodontol., 75:453–463, 2004.

Brown DL, Desai K, Vakili BA, Nouneh C, Lee HM and Golub LM: Metalloproteinase inhibition with sub‑antimicrobial doxycycline to prevent acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol., 24:733–738, 2004.

Brown DL, Golub LM and Thomas JG: Sub‑antimicrobial doses of tetracyclines. Arterioscler. Thromb. Vasc. Biol., 24:e163, 2004.

Steinberg J, Gatto LA, Schiller H, Lee HM, Golub LM and Nieman G: Chemically modified tetracycline prevents septic shock and acute respiratory distress syndrome. Shock, 24:348–356, 2005.

Reinhardt RA, Lee HM, Schmid M, Payne JB and Golub LM: Biochemical measures of inflammation and bone turnover during healing. J. Oral Maxillofac. Surg., 63:1455–1460, 2005.

Kocer SS, Walker S, Zerler B, Golub LM and Simon SR: Metalloproteinase inhibitors block Bacillus anthracis lethal factor activity. Infect. Immun., 73:7548–7557, 2005.

Sandler C, Ekokoski E, Lindstedt KA, Vainio PJ, Finel M, Sorsa T, Kovanen PT, Golub LM and Eklund KK: Chemically modified tetracycline inhibits histamine release in mast cells. Inflam. Res., 54:304–312, 2005.

Sandler C, Nurmi K, Lindstedt K, Sorsa T, Golub LM, Kovanen PT and Eklund KK: Chemically modified tetracyclines induce apoptosis in mast cells. J. Internat. Immunopharmacol., 5:1611–1621, 2005.

Sorsa T and Golub LM: Excessive inhibition of matrix metalloproteinases in periodontal disease. Oral Dis., 11:408–409, 2005.

Polson AM, Bouwsma OJ, McNamara TF and Golub LM: Enhancement of alveolar bone formation by tetracycline administration in squirrel monkeys. J. Appl. Res. Clin. Dent., 2:32–42, 2005.

Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen YT and Simon SR: Inhibition of breast cancer cell extracellular matrix degradation by chemically modified tetracyclines. Ann. Med., 37:450–460, 2005.

Golub LM and Joshi V: How the tadpole lost its tail; host modulation concepts in periodontal disease. Perio/India, Lecture No. 1:1–10, 2005.

Golub LM, Payne JB, Reinhardt RA and Nieman G: Can systemic diseases co‑induce periodontitis? J. Dent. Res., 85:102–105, 2006.

Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, Golub LM, Brown DL and Mantyla P: Matrix metalloproteinases in periodontal inflammation. Ann. Med., 38:306–321, 2006.

Walker C, Puumala S, Golub LM, Stoner JA, Reinhardt RA, Lee HM and Payne JB: Sub‑antimicrobial doxycycline effects on osteopenic bone loss. J. Periodontol., 78:1590–1601, 2007.

Reinhardt RA, Stoner JA, Golub LM, Lee HM and Payne JB: Efficacy of sub‑antimicrobial doxycycline in postmenopausal women. J. Clin. Periodontol., 34:768–775, 2007.

Preston RD, Meinberg TA, Payne JB, Schmid MJ, Lee HM, Golub LM, Marx DB and Reinhardt RA: Inflammatory mediator release after bone grafting. J. Clin. Periodontol., 34:797–804, 2007.

Payne JB, Stoner JA, Nummikoski PV, Reinhardt RA, Goren AD, Wolff MS, Lee HM, Lynch JC, Valente R and Golub LM: Sub‑antimicrobial doxycycline effects on alveolar bone loss. J. Clin. Periodontol., 34:776–787, 2007.

Leskinen MJ, Eklund KK, Sorsa T, Golub LM, Kovanen PT and Lindstedt KA: Inhibition of smooth muscle cell proliferation by chemically modified tetracycline. Coron. Artery Dis., 18:663–667, 2007.

Xu L, Yu Z, Lee HM, Wolff MS, Golub LM and McNamara TF: Characteristics of collagenase‑2 from gingival crevicular fluid and peri‑implant sulcular fluid in periodontitis and peri‑implantitis patients. Acta Odontol. Scand., 66:219–224, 2008.

Goren AD, Dunn SM, Wolff M, van der Stelt PF, Colosi DC and Golub LM: Digital subtraction radiography as a tool to assess alveolar bone changes in periodontitis patients treated with sub‑antimicrobial doxycycline. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 106:e40–e45, 2008.

Golub LM, Lee HM, Stoner JA, Sorsa T, Goren AD and Payne JB: Sub‑antimicrobial‑dose doxycycline modulates gingival crevicular fluid biomarkers in postmenopausal osteopenic women. J. Periodontol., 79:1409–1418, 2008.

Reinhardt TA, Stoner JE, Golub LM, Lee HM and Payne JB: Gingival crevicular fluid biomarkers associated with progressive periodontitis. J. Periodontol., 81:252–259, 2010.

Gu Y, Lee HM, Sorsa T, Simon SR and Golub LM: Doxycycline inhibits mononuclear cell‑mediated connective tissue breakdown. FEMS Immunol. Med. Microbiol., 58:218–225, 2010.

Golub LM, Lee HM, Stoner JA, Reinhardt RA, Sorsa T, Goren AD and Payne JB: Doxycycline effects on serum bone biomarkers in postmenopausal women. J. Dent. Res., 89:644–649, 2010.

Payne JB, Stoner JA, Lee HM, Nummikoski PV, Reinhardt RA and Golub LM: Serum bone biomarkers and oral/systemic bone loss in humans. J. Dent. Res., 90:747–751, 2011.

Payne JB, Golub LM, Stoner JA, Lee HM, Reinhardt RA, Sorsa T and Slepian MJ: Sub‑antimicrobial doxycycline effects on systemic inflammation biomarkers. J. Amer. Dent. Assoc., 142:262–273, 2011.

Golub LM and Greenwald RA: Clinical applications of non‑antibacterial tetracyclines. Pharmacological Res., 63:97–156, 2011.

Golub LM: Introduction and background. Pharmacological Res., 63:99–101, 2011.

Payne JB and Golub LM: Using tetracyclines to treat osteoporotic bone loss. Pharmacological Res., 63:121–129, 2011.

Golub LM and Greenwald RA: Clinical applications of non‑antibacterial tetracyclines. Pharmacological Res., 64:549–630, 2011.

Golub LM and Greenwald RA: Preface. Pharmacological Res., 64:549–550, 2011.

Gu Y, Lee HM, Sorsa T, Salminen A, Ryan ME, Slepian MJ and Golub LM: Non‑antibacterial tetracyclines modulate mediators of periodontitis and cardiovascular disease. Pharmacological Res., 64:573–579, 2011.

Shreyas R, Kendrick D, Sadowitz BD, Satalin JM, Golub LM and Nieman G: Pleiotropy of chemically modified tetracycline‑3 in sepsis and acute respiratory distress syndrome. Pharmacological Res., 64:580–589, 2011.

Gu Y, Lee HM, Simon SR and Golub LM: Chemically modified tetracycline‑3 inhibits elastase. Pharmacological Res., 64:595–601, 2011.

Roy SK, Kubiak BD, Albert SP, Vieau CJ, Gatto LA, Golub LM, Lee HM, Sookhu S, Vodovotz Y and Nieman GF: Chemically modified tetracycline‑3 prevents acute respiratory distress syndrome. Shock, 37:424–432, 2012.

Zhang Y, Gu Y, Lee HM, Hambardjieva E, Vrankova K, Golub LM and Johnson F: Polyenolic inhibitors of matrix metalloproteinases. Curr. Med. Chem., 19:4348–4358, 2012.

Zhang Y, Golub LM, Johnson F and Wishnia A: pKa, zinc‑binding and albumin binding of curcumin derivatives. Curr. Med. Chem., 19:4367–4375, 2012.

Payne JB, Golub LM and Stoner JA: Response to Bretz review. J. Evid. Based Dent. Pract., 12:178–179, 2012.

Gu Y, Walker C, Ryan ME, Payne JB and Golub LM: Non‑antibacterial tetracycline formulations in dentistry and medicine. J. Oral Microbiol., 4:19227, 2012.

Walker S and Golub LM: Host modulation therapy for periodontal disease. Oral Health, 2012.

Goldberg MB, Golub LM, Lee HM and Tenenbaum C: Refractory periodontitis: systemic implications. J. Interdiscipl. Med. Dent. Sci., 1:101, 2013.

Salminen A, Pussinen PJ, Payne JB, Stoner JA, Jauhiainen M, Golub LM and Lee HM: Sub‑antimicrobial doxycycline increases cholesterol efflux. Inflammation Res., 62:711–720, 2013.

Botchkina GI, Zuniga ES, Rowehl RH, Park R, Bhalla R, Ivanov AR, Bialkowska AB, Johnson F, Golub LM, Zhang Y, Ojima I and Shroyer KR: Prostate cancer stem cell‑targeted efficacy of polyenolic zinc‑binding curcuminoid. PLoS ONE, 8:e69884, 2013.

Payne JB, Nummikoski PV, Thompson DM, Golub LM and Stoner JA: Association between clinical and radiographic periodontitis measurements. J. Periodontol., 84:1382–1390, 2013.

Antonelli AC, Zhang Y, Golub LM, Johnson F and Simon SR: Inhibition of anthrax lethal factor by curcumin derivatives. J. Enzyme Inhib. Med. Chem., 2013.

Gu Y, Lee HM, Napolitano N, Clemens M, Zhang Y, Sorsa T, Johnson F and Golub LM: 4‑Methoxycarbonyl curcumin inhibits periodontal inflammation. Mediators Inflamm., 2013.

Elburki MS, Rossa C, Guimarães MR, Goodenough M, Lee HM, Johnson F, Zhang Y, Curylofo FA and Golub LM: Chemically modified curcumin reduces experimental periodontal disease. Mediators Inflamm., 2014.

Payne JB, Golub LM and Thiele GM: Periodontitis and rheumatoid arthritis. Curr. Oral Health Rep., 2014.

Jones J, Golub LM, Gu Y, Ryan ME and Masse D: Is periodontitis infectious or inflammatory? Oral Health, 2015.

Sadowsky D, Nieman G, Barclay D, Mi Q, Zamora R, Constantine G, Golub LM, Lee HM, Roy S, Gatto LA and Vodovotz Y: Impact of chemically modified tetracycline‑3 on porcine sepsis. Int. J. Burn Trauma, 5:22–35, 2015.

Lauhio A, Tervahartiala T, Leppilahti J, Golub LM, Ryan ME and Sorsa T: Doxycycline in extended‑spectrum beta‑lactamase colonization. Clin. Infect. Dis., 2015.

Donley T, Jones JJ, Golub LM, Gu Y and Ryan ME: Addressing inflammation in periodontal and systemic diseases. Oral Health, 2015.

Golub LM, Elburki MS, Walker C, Ryan ME, Sorsa T, Tenenbaum H, Goldberg M, Wolff M and Gu Y: Non‑antibacterial tetracycline formulations as host modulators. Int. Dent. J., 2016.

Elburki MS, Moore DD, Terezakis NG, Zhang Y, Lee HM, Johnson F and Golub LM: Chemically modified curcumin reduces diabetes‑associated connective tissue breakdown. J. Periodont. Res., 2016.

Xu Y, Ge L, Abdel‑Razek O, Jain S, Liu Z, Hong Y, Nieman G, Johnson F, Golub LM, Cooney RN and Wang G: Chemically modified curcumin reduces lung injury. Shock, 45:375–384, 2016.

Zhang Y, McClain SA, Lee HM, Elburki MS, Yu H, Gu Y, Wolff M, Johnson F and Golub LM: Chemically modified curcumin normalizes wound healing in diabetes. J. Diabetes Res., 2016.

Elburki MS, Rossa C, Guimarães‑Stabili MR, Lee HM, Curylofo‑Zotti FA, Johnson F and Golub LM: Chemically modified curcumin inhibits inflammation‑induced bone loss. Inflammation, 40:1436–1449, 2017.

Curylofo FA, Elburki MS, Oliveira PA, Cerri PS, Santos LA, Lee HM, Johnson F, Golub LM, Rossa C and Guimarães‑Stabili MR: Natural versus chemically modified curcumin in experimental periodontitis. Archs Oral Biol., 91:42–50, 2018.

Mallangada N, Vargas J, Thomas S, DiGiovanni M, Vaeth BM, Nemesure M, Wang R, LaComb JF, Williams JL, Golub LM, Johnson F and Mackenzie GG: Tricarbonylmethane agent reduces pancreatic tumor growth. Mol. Carcinog., 57:1130–1143, 2018.

Golub LM, Gu Y, Tenenbaum H, Goldberg M and Sorsa T: Point‑by‑point statement on periodontal host‑modulation therapy. Oral Health, 2018.

Brandao DA, Spolidorio LC, Johnson F, Golub LM, Guimaraes‑Stabili MR and Rossa C: Chemically modified curcumin dose‑response in experimental periodontitis. J. Periodontol., 2018.

Wang HH, Lee HM, Raja V, Hou W, Iacono VJ, Scaduto J, Johnson F, Golub LM and Gu Y: Enhanced efficacy of chemically modified curcumin in periodontal disease. J. Exp. Pharmacol., 2019.

Thompson DM, Lee HM, Stoner JA, Golub LM, Nummikoski PV and Payne JB: Alveolar bone density and gelatinase levels in postmenopausal women. J. Periodontal Res., 2019.

Brandão DA, Spolidorio LC, Johnson F, Golub LM, Guimarães‑Stabili MR and Rossa C: Dose‑response assessment of chemically modified curcumin. J. Periodontology, 90:535–545, 2019.

Alvarez C, Cavalla F, Cordova LA, Monasterio G, Hernandez M, Heymann D, Garlet G, Sorsa T, Parnanen P, Lee HM, Golub LM, Vernal R and Kantarci A: Osteoimmunology of oral and maxillofacial diseases. Frontiers Immunol., 10:1664, 2019.

Golub LM and Lee HM: Periodontal therapeutics and host‑modulation agents. Periodontology 2000, 82:186–204, 2020.

Deng J, Golub LM, Lee HM, Lin MC, Bhatt HD, Hong HL, Johnson F, Scaduto J, Zimmerman T and Gu Y: Chemically modified curcumin therapy for natural periodontitis in dogs. J. Exp. Pharmacol., 2020.

Golub LM, Raisanen IT, Sorsa T and Preshaw P: Pharmacologic strategy for peri‑implantitis. Diagnostics, 10:1050, 2020.

Gu Y, Golub LM, Lee HM, Hou W and Ryan ME: Periodontal disease in acute coronary syndrome patients. Am. J. Dent., 2021.

Deng J, Golub LM, Lee HM, Bhatt HD, Hong H, Johnson F, Scaduto J, Zimmerman T and Gu Y: Short‑term curcumin therapy for canine periodontitis. Frontiers Dent. Med., 2021.

Cardoso E, Fine N, Glogauer M, Johnson F, Goldberg M, Golub LM and Tenenbaum HC: Periodontal research and COVID‑19. Frontiers Dent. Med., 2021.

Golub LM, Lee HM and Walker S: Host‑modulation therapy for dental implants. Int. J. Phys. Med. Rehabil., 9:S5, 2021.

Sorsa T, Sahni V, Buduneli N, Gupta S, Raisanen IT, Golub LM, Lee HM, Patila T, Bostanci N, Meurman J, Parnanen P, Nwhator SO, Singla M and Gauba K: Active matrix metalloproteinase‑8 testing in COVID‑19 pandemic. Expert Rev. Proteomics, 2021.

Chang S, Glogauer M, Golub LM, Bacigalupo J, Sorsa T, Preshaw PM and Tenenbaum HC: Host‑modulation therapy for peri‑implantitis. Oral Health, 2021.

Deng J, Golub LM, Lee HM, Raja V, Johnson F, Kucine A, Lee W, Xu TM and Gu Y: Modified curcumin promotes resolvin‑like activity and reduces bone loss. J. Inflammation Res., 2021.

Golub LM and Lee HM: Host modulation therapy for dermatologic collagenolytic diseases. J. Clin. Exp. Dermatol. Res., 2021.

Bhatt HD, Golub LM, Lee HM, Kim J, Zimmerman T, Deng J, Hong H, Johnson F and Gu Y: Pharmacokinetics of a novel chemically modified curcumin. J. Exp. Pharmacol., 2022.

Bhatt HD, Golub LM, Lee HM, Kim J, Zimmerman T, Deng J, Hong H, Johnson F and Gu Y: Long‑term efficacy of chemically modified curcumin in diabetes. J. Inflammation Res., 2023.

Deng J, Golub LM, Lee HM, Bhatt HD, Johnson F, Xu TM and Gu Y: Modified curcumin resolves inflammation by promoting macrophage polarization. Sci. Rep., 13:15513, 2023.

Goenka S and Golub LM: Effects of chemically modified tetracyclines on human melanogenesis. Drugs Drug Candidates, 2:810–826, 2023.

Bacigalupo J, Golub LM, Sorsa T, Lee HM, Gu Y and Walker SG: Managing tissue health around teeth and implants. J. Community Med. Public Health Rep., 2024.

Golub LM, Lee HM, Bacigalupo J and Gu Y: Host modulation therapy in periodontitis. Frontiers Dent. Med., 2024.

Gnocchi C, Lenzuni M, Fiorentini F, Merino D, Summa M, Golub LM, Lee HM, Johnson F, Bertorelli R, Suarato G and Athanassiou A: Zein microparticles loaded with chemically modified curcumin for wound healing. J. Drug Deliv. Sci. Technol., 2024.

Dai Q, Lee HM, Giordano A, Chiang FP, Walker S, Delgado‑Ruiz R, Johnson F, Golub LM and Gu Y: Chemically modified curcumin and dental resin biodegradation. Frontiers Oral Health, 2025.

Gu Y, Golub LM, Lee HM and Walker S: Diabetes, periodontal disease and host‑modulation therapy. Frontiers Clin. Diabetes Healthc., 2025.

Puentes R, Mirzadzare N, Hannawayya R, Perez Perez L, Dies A, Tiedje K, Derakhshani A, Young D, Johnson F, Golub LM, Scaduto J, Dufour A and Cobo ER: Curcumin derivative mitigates swine dysentery. Int. Immunopharmacol., 163:115312, 2025.

Lahiri P, Young D, Penner R, Lesack K, Dias AP, de Buck J, Orsel K, Hollenberg MD, Johnson F, Golub LM, Scaduto J, Dufour A and Cobo ER: Proteolytic dysfunction in bovine digital dermatitis. Commun. Biol., 8:1503, 2025.

Sorsa T, Golub LM, Thomas J, Leone P, Anil S and Uitto VJ: Matrix metalloproteinases in periodontitis and peri‑implantitis. J. Periodontal Res., 2026.

Book Chapters

Golub LM: Gingival crevice fluid. In: Baer PN and Morris ML (Eds.): Textbook of Periodontics. Philadelphia, PA: J. B. Lippincott Company, 1977.

Chilton N, Miller M, Hazen S and Golub LM: Diagnosis and epidemiology of periodontal diseases. In: Klavan B, Genco R, Löe H, Page R, Stern I, Thrope J and Barrington E (Eds.): International Conference on Research in the Biology of Periodontal Disease. Chicago, IL: University of Illinois, pp. 92–151, 1977.

Schneir M and Golub LM: The effect of streptozotocin diabetes on collagen metabolism. In: Agarwal MK (Ed.): Streptozotocin: Fundamentals and Therapy. Elsevier/North Holland Biomedical Press, pp. 161–182, 1981.

Ciancio SG and Golub LM: Systemic agents. Chapter 9. In: Löe H and Kleinman DV (Eds.): Dental Plaque Control Measures and Oral Hygiene Practices. Washington, DC: IRL Press, pp. 215–224, 1986.

Greenwald RA and Golub LM (Editors): Inhibition of matrix metalloproteinases: Therapeutic potential. Annal. N.Y. Acad. Sci., 732:507 pages, 1994.

Greenwald RA and Golub LM (Editors): Non‑antibiotic properties of tetracyclines. Advances Dent. Res., 12:176 pages, 1998.

Greenwald RA, Zucker S and Golub LM (Eds.): Inhibition of matrix metalloproteinases II: Therapeutic applications. Ann. N.Y. Acad. Sci., 878:761 pages, 1999.

Greenwald RA and Golub LM (Eds.): Chemically Modified Tetracyclines (CMTs). Curr. Medicinal Chem., 8:89 pages, 2001.

Ramamurthy NS, Pirila E, Lee H, Maisi P, McClain S, Sorsa T and Golub LM: Delayed wound healing, altered collagen level and keratinocyte growth factor expression in ovariectomized rat skin is normalized by estrogen or chemically modified doxycycline. In: Schneider HPG (Ed.): Menopause: The State of the Art. Section VII. New York, NY: The Parthenon Publishing Group, pp. 236–244, 2003.

Golub LM and Greenwald RA (Editors): Special issue (Part 1): Clinical applications of non‑antibacterial tetracyclines. Pharmacological Res., 63(2):97–156, 2011.

Golub LM and Greenwald RA (Editors): Special issue (Part 2): Clinical applications of non‑antibacterial tetracyclines. Pharmacological Res., 64(6):549–630, 2011.

Golub LM and Lee HM: Periodontal therapeutics: Current host‑modulation agents and future directions. Periodontology 2000.

1969-1971: Principal Investigator (PI): "The Effect of Fluoride on Bone Collagen Formation, Maturation, and Resorption," Medical Research Council (MRC) of Canada; $16,000.

1971-1972: PI: "The Effect of Fluoride and Ascorbic Acid on Bone Collagen Synthesis, Resorption, and Cross-Linking," MRC of Canada; $9,500.

1972-1973: PI:  "Collagen Metabolism of Human Gingiva:  The Effects of Age and Inflammation," MRC of Canada; $12,750.

1973-1974: PI:  "Collagen Metabolism of Human Gingiva:  The Effects of Age and Inflammation," MRC of Canada; $16,312.

1974-1975: Co-I:  "The Effect of an Amine Fluoride Dentifrice on Gingival Health and Plaque Formation", Menley and James, Philadelphia, Pennsylvania; $22,200.

1975-1977: PI: "Gingival Collagen Metabolism in Humans with Diabetes Mellitus", Long Island Jewish/Hillside Medical Center, New Hyde Park, New York; $8,365.

1975-1978: PI:  "Gingival Collagen Metabolism in Health and Disease," National Institute of Dental Research (NIH); $163,001.

1976-1978: PI:  "The Effect of Diabetes on the Periodontal Breakdown in Germ-Free Animals", N.Y. State Diabetes Association; $17,500.

1978-1981: PI:  "Gingival Collagen Metabolism in Health and Disease," National Institute of Dental Research (NIH); $297,530.

1981-1984: PI:  "The Effect of Diabetes on Gingival Collagenase and Periodontal Disease in Germ-Free and Conventional Rats", The Kroc Foundation for Medical Research; $106,432.

1981-1984: PI:  "Gingival Collagen Metabolism in Health and Disease," National Institute of Dental Research (NIH); $386,789.

1984-1988: PI:  "Gingival Collagen Metabolism in Health and Disease," National Institute of Dental Research (NIH); $748,000.

1985-1991: PI:  "Development of Anti-Collagenase Chemotherapeutic Agents," Johnson and Johnson Products, Inc.; $480,000.

1988-1998: PI:  "Gingival Collagen Metabolism in Health and Disease," National Institute of Dental Research MERIT Award (NIH); $2,678,524.

1990-1993: Co-I:  "Effect of Tetracyclines on Bone Cell Function in vitro," National Institute of Dental Research (NIH); $138,251.

1991-1992: PI:  "New CMTs: Potential Medical Applications," Kuraray Chemical Co., Kurashiki, Japan; $125,000.

1991-1992: Co-PI: Small instrumentation grant. NIH; $6,125.

1992-1994: Co-I:  Tetracyclines and osteoblast collagenase.  NYU subcontract (NIDR/NIH), $25,687.

1992-1995: PI: Development of anti-collagenase chemotherapeutic agents.  CollaGenex, Inc., $399,800.

1993-1994: Co-PI:  Center for Biotechnology, SUNY at Stony Brook; $15,000.

1993-1996: Co-PI:  "Therapeutic potential of non-antimicrobial tetracyclines," NRSA training grant as supervisor of Dr. Maria Ryan, NIDR (NIH); $97,500.

1993-1998: Co-PI:  Supervisor for Dr. Maria Ryan:  Physician Scientist Award, NIH; $424,151.

1994: Co-PI:  NIH Grant in support of N.Y. Acad. Sciences meeting co-chaired by Greenwald, R.A. & Golub, L.M., Tampa, FL, Jan. 19-22, 1994; $15,300.

1994-1995: Co-PI:  "Low-dose doxycycline periodontal study,"  ACTech, Inc. & CollaGenex, Inc.; $45,000.

1994-1997: PI:  "Collagenase inhibitors," CollaGenex, Inc.; $240,000.

1994-1997: Co-I: "Tetracyclines and osteoblast collagenase,"  NYU subcontract(NIH); $116,352.

1994-1997: PI:  Vice-President's Research Infrastructure Grant, Research Foundation, SUNY at Stony Brook; $180,000.

1997-1998: PI:  "Impaired wound healing in skin of Type I and Type II diabetic rats: Effect of topical anti- collagenases,"  CollaGenex, Inc. and The Stony Brook Center for Advanced Biotechnology; $10,750.

1997-1998: PI: "Dynamic histomorphometric studies on bone remodeling in estrogen-deficiency osteoporosis: Effect of chemically-modified tetracyclines," The Stony Brook Center for Advanced Biotechnology and CollaGenex, Inc.; $55,000.

1998: Co-Investigator (with Greenwald, R.A., P.I.):  "Matrix metalloproteinase inhibitors: Therapeutic aspects,"  NIDR (NIH) grant in partial support of a N.Y. Acad. Sci. conference, Tampa, FL, Oct. 21-24; $30,880 (direct funds).

1998: Co-Investigator (with Greenwald, R.A., P.I.):  "Non-antibiotic properties of tetracyclines," NIDR (NIH) grant in partial support of an international research  conference, Garden City, NY, Nov. 12-14; $14,950 (direct funds).

1998-1999: PI: “Naturally occurring periodontitis in the beagle dog: Therapeutic potential of a chemically modified tetracycline (CMT-8),” Heska Corp., $33,500.

1997-2000: Co-Investigator (with Gruber, B.):  NIH grant  (P.I., N. Edelman, & Co-P.I., M. Gelato; GCRC, University Hospital, SUNY at Stony Brook), sub-project entitled: "The effect of doxycycline/MMP inhibition on bone remodeling in osteoporotic post-menopausal women"; $30,000 (direct funds).

1. 1998-2001 Co-PI: “Pharmacologic Characteristics and Therapeutic Properties of Novel Chemically-Modified Tetracycline Analogs, ”CollaGenex Pharmaceuticals, Inc.; $1,570,165.
2. 1999-2001 PI: “Vice-President’s Research Infrastructure Grant, Research Foundation, SUNY at Stony Brook; $200,000.
3. 2000-2001 PI: “Research Infrastructure Grant (Clinical and Radiological Oral Biology Research Suite)” V.P. for Research, V.P. for HSC, and Dean, School of Dental Medicine, SUNY at Stony Brook, $70,000.

2000-2001: Co-I: “A study to investigate the variability in gingival crevicular fluid of markers of inflammation and tissue destruction in patients with adult periodontitis.” Astra Zeneca UK, Ltd., $113,520.

2001-2009: Co-PI: “Low-dose doxycycline effects on osteopenic bone loss.” NIDCR/NIH, $2,270,894.

2001-2002: PI: “General research support on chemically modified tetracyclines.”  CollaGenex Pharmaceuticals, Inc., $25,390.

1. 2001-2002 PI: “Anti-fungal activity of non-antimicrobial chemically-modified tetracyclines.” CollaGenex Pharmaceuticals, Inc., $32,000.
2. 2001-2002 PI: “Chemically-modified tetracyclines as unexpected anti fungal agents.” Center for Advanced Biotechnology, SUNY at Stony Brook, $32,000.
3. 2002-2003 Co-PI: “The therapeutic potential of a chemically modified non-antimicrobial tetracycline: a short-term study on surrogate markers of periodontal disease in humans.” CollaGenex Pharmaceuticals, Inc., $155,450.
4. 2002-2003 PI: “Initial support for a Clinical research coordinator,” Graduate Research Initiative, VP for Research & VP for HSC, SUNY at Stony Brook, $200,000.
5. 2003-2005 Co-I: “Treatment of anthrax with nonantimicrobial tetracyclines.” NIH, $451,500.
6. 2004 PI: “General support for research on tetracycline analogs”. Collagenex Pharmaceuticals, Inc., $35,000.

2005: Co-PI: “General support for research on chemically-modified tetracyclines and periodontal disease.” Collagenex Pharmaceuticals, Inc., $75,000.

2005: PI: “Potential efficacy of Letrozole in the treatment of breast cancer in rats” subcontract from Upstate Medical University, Dept of OB/GYN $9,000.

2005-2008: Co-I: “Modified tetracycline effect on sepsis-induced mortality.” NIH (STTR), Nat. Heart, Lung & Blood Inst. (NHLBI), $176,985. .

2007-2010: Co-PI: “Low-dose doxycycline effects on diagnostic biomarkers of cardiovascular disease in post-menopausal osteopenic women.” NIDCR (NIH), $301,767.

2007-2008: Co-PI: “Chemically-modified tetracyclines and gram-positive bacterial physiology.”  Collagenex Pharmaceuticals, Inc., $54,000.

2007-2010: Co-PI: “A model of periodontal bone loss in diabetic rats” Enzo Pharmaceuticals Inc. $20,000.00.

2007-2013: PI: “New MMP and cytokine inhibitors - - a novel class of compounds.” Center for Advanced Biotechnology and V.P. for Research Commercialization Fund, SUNY at Stony Brook. $260,000.

2013-2015: Co-investigator on a “Targeted Research Opportunities (TRO) grant from the Stony Brook School of Medicine Office of the Vice President for Research titled: “Doxycycline Treatment of Insulin Resistance in Obesity”, Dr. M. Gelato (P.I.) $60,000 (2013-2015).

2015-2016: Co-investigator with G. Nieman (P.I.) (SUNY Upstate Medical School, Syracuse, NY) on a “cross-disciplinary, multi-campus” research grant submitted to SUNY/Research Foundation collaboration Fund (Albany, NY) on “chemically-modified curcumins: a novel treatment for acute respiratory distress syndrome”, $100,000.

2015-2016: PI: “Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model”, STTR/NIDCR (NIH) Phase I with Traverse Biosciences, Inc., $205,709.

2016-2017: Co-investigator, “A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence”, Department of Defense (DoD), U.S. Army, $164,689.00.

2016-2019: PI: “Initial Pre-Clinical Safety Assessment of TRB-N0224”, Center for Biotechnology, Applied Research & Development (ARAD) program, $37,711.00.

2017-2021: PI: “Pre-Clinical Development of TRB-N0224, a Novel Chemically Modified Curcumin, for the Treatment of Periodontal Disease”, STTR/NIDCR (NIH) Phase II, 5R42DE024946 - 03 with Traverse Biosciences, Inc., $1,320,432.00.

2019-2020: Co-PI: “Design, Synthesis and Evaluation of Novel Pleiotropic Matrix Metalloproteinase (MMP) Inhibitors for the Treatment and Control of Inflammatory Bowel Disease (IBD)”, Center for Biotechnology (CFB), $10,224.00.

2020-2023: Consultant, Alberta Agriculture and Forestry, National Research Council of Canada, U of Calgary, Veterinary Medicine.  “Metalloproteinases in ulcerative digital dermatitis, a novel target for reparative therapies”.  Eduardo R Cobo, M Hollenberg and Traverse Biosciences Inc,. $226,288

2021-2022: Co-Investigator with CMTx Biotech, Inc., NIH grant # 1U34 TR003593-01, from National Center for Advancing Translational Sciences Special Emphases Panel NTU COVID-19. Project title: Repurposing Incyclinide for the Treatment of Hospitalized COVID-19 Patients. $315.000.

2022-2024: Consultant to an approved proposal from Alberta Agriculture and Forestry, Canada, No. 2022F038R titled: “An antibiotic-free treatment for post-weaning diarrhea in pigs targeting proteases in the inflamed gut” to University of Calgary, PI is Dr. Eduardo Cobo, Project Start Date 03/01/2022 – 02/29/2024, total Funding for 2 years = $515,500.00 (Canadian dollar).

2023-2025: Scientific Adviser, CMTx Biosciences Inc. Funding Agency: National Institutes of Health (NIH) Type: Phase I / II Fast-Track Small Business Technology Transfer (STTR) Title: “Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome” Partner: SUNY Upstate Medical University, Project Funding: $2,295,776. 1R42HL166050-01.

2023-2024: Scientific Adviser, CMTx Biotech, Inc., STTR/NIH, titled “Novel Small Molecule Drug Candidate for the Prevention of Bronchopulmonary Dysplasia,” in partnership with SUNY Upstate Medical University (PD/PI: Dr. Michael Kollisch-Singule) in the amount of $376,752 for the period 05/03/2023-04/30/2024.

2023-2025: Scientific Adviser (no funds), CMTx Biosciences Inc. Funding Agency: National Heart, Lung, and Blood Institutes. Type: Phase I / II Fast-Track Small Business Technology Transfer (STTR) Title: “Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome” Partner: SUNY Upstate Medical University, (PD/PI: Dr. Michael Kollisch-Singule / Dr. Juntao Luo).Project Funding: $2,295,776. 1R42HL166050-01.

2024-2025: Scientific Adviser (no funds), CMTx Biotech Inc. from National Institute of Allergy and Infectious Diseases, STTR/SBIR titled: “A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury,”  1R41AI187083-01, in partnership with the U. of Colorado Anschutz Medical Campus (PI: Livia Veress, MD). Project funding: $299,993 for period 07/09/2024 – 6/30/2025.

2025-2026 Scientific Adviser (no funds), CMTx Biotech Inc., Funding Agency: National Heart, Lung, and Blood Institutes. Type: Phase I / II Fast-Track Small Business Technology Transfer (STTR) Title: “Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome” Partner: SUNY Upstate Medical University, (PD/PI: Dr. Michael Kollisch-Singule / Dr. Juntao Luo).Phase II Project Funding: $887,354 for 1st year.

2025-2026 Scientific Adviser (no funds), CMTx Biotech Inc. from National Institute of Allergy and Infectious Diseases, STTR/SBIR titled: “A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury,”  1R41AI187083-02, in partnership with the U. of Colorado Anschutz Medical Campus (PI: Livia Veress, MD).2nd year subaward.  Project funding: $295,715 for period 07/09/2025 – 6/30/2026.

Golub LM, 1973. Device and method for the quantitative measurement of fluid on paper strips. U.S. Patent 3,753,099, issued August 14, 1973.

Golub LM, 1982. In vivo method of determining leucocyte migratory activity levels. U.S. Patent 4,366,144, issued December 28, 1982.

Golub LM, 1987. Inhibition of mammalian collagenolytic enzymes by tetracyclines. U.S. Patent 4,666,897, issued May 19, 1987.

Golub LM, 1987. Non‑antibacterial tetracycline compositions possessing anti‑collagenolytic properties and methods of preparing and using same. U.S. Patent 4,704,383, issued November 3, 1987.

Golub LM, 1990. Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis. U.S. Patent 4,925,833, issued May 15, 1990.

Golub LM, 1990. Non‑antibacterial tetracycline compositions possessing anti‑collagenolytic properties and methods of preparing and using same. U.S. Patent 4,935,411, issued June 19, 1990.

Golub LM, 1990. Non‑antibacterial tetracycline compositions possessing anti‑collagenolytic properties and methods of preparing and using same. U.S. Patent 4,935,412, issued June 19, 1990.

Golub LM, 1991. Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines. U.S. Patent 5,045,538, issued September 3, 1991.

Golub LM, 1993. Non‑antibacterial tetracycline compositions possessing antiplaque properties. U.S. Patent 5,223,248, issued June 29, 1993.

Golub LM, 1993. Method to reduce connective tissue destruction. U.S. Patent 5,258,371, issued November 2, 1993.

Golub LM, 1994. Composition comprising non‑steroidal anti‑inflammatory agent tenidap and effectively non‑antibacterial tetracycline. U.S. Patent 5,308,839, issued May 3, 1994.

Golub LM, 1994. Composition comprising flurbiprofen and effectively non‑antibacterial tetracycline to reduce bone loss. U.S. Patent 5,321,017, issued June 14, 1994.

Golub LM, 1994. Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency. U.S. Patent RE34,656, issued July 5, 1994.

Golub LM, 1995. Composition comprising indomethacin and effectively non‑antibacterial tetracycline to reduce bone loss. U.S. Patent 5,459,135, issued October 17, 1995.

Golub LM, 1996. Inhibition of excessive phospholipase A₂ activity and/or production by non‑antimicrobial tetracyclines. U.S. Patent 5,523,297, issued June 4, 1996.

Golub LM, 1996. Tetracyclines including non‑antimicrobial chemically modified tetracyclines inhibit excessive glycosylation of collagen and other proteins during diabetes. U.S. Patent 5,532,227, issued July 2, 1996.

Golub LM, 1998. Non‑antibacterial tetracycline compositions for the prevention and treatment of root caries. U.S. Patent 5,770,588, issued June 23, 1998.

Golub LM, 1998. Serine proteinase inhibitory activity by hydrophobic tetracycline. U.S. Patent 5,773,430, issued June 30, 1998.

Golub LM, 1998. Method of using tetracycline compounds for inhibition of endogenous nitric oxide production. U.S. Patent 5,789,395, issued August 4, 1998.

Golub LM, 1998. Promotion of wound healing by chemically modified tetracyclines. U.S. Patent 5,827,840, issued October 27, 1998.

Golub LM, 1998. Treatment of aortic and vascular aneurysms with tetracycline compounds. U.S. Patent 5,834,449, issued November 11, 1998.

Golub LM, 1998. Method of inhibiting cancer growth. U.S. Patent 5,837,696, issued November 17, 1998.

Golub LM, 1999. Method for inhibiting expression of inducible nitric oxide synthase with tetracycline. U.S. Patent 5,919,775, issued July 6, 1999.

Golub LM, 1999. Therapeutic method for management of diabetes mellitus. U.S. Patent 5,929,055, issued July 27, 1999.

Golub LM, 1999. Method of preventing acute lung injury. U.S. Patent 5,977,091, issued November 2, 1999.

Golub LM, 1999. Combination of bisphosphonate and tetracycline. U.S. Patent 5,998,390, issued November 2, 1999.

Golub LM, 2000. Method of using tetracycline compounds to enhance interleukin‑10 production. U.S. Patent 6,015,804, issued January 18, 2000.

Golub LM, 2000. Inhibition of excessive phospholipase A₂ activity and/or production by non‑antimicrobial tetracycline. U.S. Patent 6,043,231, issued March 28, 2000.

Golub LM, 2000. A novel inhibitor of cataract formation. WO Patent 2000/018353, issued April 6, 2000.

Golub LM, 2000. Method of inhibiting cancer growth. U.S. Patent 6,100,248, issued August 8, 2000.

Golub LM, 2000. Combination of bisphosphonate and tetracycline. U.S. Patent 6,114,316, issued September 5, 2000.

Golub LM, 2000. Diagnostic method for detection of periodontitis or peri‑implantitis. U.S. Patent 6,143,506, issued November 7, 2000.

Golub LM, 2001. Method of inhibiting membrane‑type matrix metalloproteinase. U.S. Patent 6,277,061, issued August 21, 2001.

Golub LM, 2001. Diagnostic method for detection of periodontitis or peri‑implantitis. U.S. Patent 6,280,687, issued August 28, 2001.

Golub LM, 2002. Method of inhibiting membrane‑type matrix metalloproteinase. U.S. Patent Application 2002/0045603, issued April 18, 2002.

Golub LM, 2002. Method of inhibiting cancer growth. U.S. Patent 6,429,204, issued August 6, 2002.

Golub LM, 2004. Method for reducing C‑reactive protein levels with non‑antibacterial tetracycline formulations. WO Patent 2004/006938, issued January 22, 2004.

Golub LM, 2004. Use of non‑antibacterial tetracycline analogs for the treatment of bacterial exotoxins. U.S. Patent Application 2004/0014731, issued January 22, 2004.

Golub LM, 2004. Method of treating sepsis‑induced acute respiratory distress syndrome. U.S. Patent Application 2004/0092491, issued May 13, 2004.

Golub LM, 2004. Method for decreasing low‑density lipoprotein levels. U.S. Patent Application 2004/0171591, issued September 2, 2004.

Golub LM, 2005. Inhibitor of cataract formation. U.S. Patent 6,914,057, issued July 5, 2005.

Golub LM, 2005. Methods of treating eczema. U.S. Patent Application 2005/0148552, issued July 7, 2005.

Golub LM, 2005. Method for reducing C‑reactive protein levels with non‑antibacterial tetracycline formulations. U.S. Patent Application 2005/0282786, issued December 22, 2005.

Golub LM, 2006. Use of low‑dose chemically modified tetracyclines to reduce inflammatory mediators. WO Patent 2006/036655, issued June 4, 2006.

Golub LM, 2007. Use of non‑antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells. U.S. Patent Application 2007/0015738, issued January 18, 2007.

Golub LM, 2007. Use of non‑antibacterial tetracycline formulations for inhibiting bacterial spores. U.S. Patent Application 2007/0015739, issued January 18, 2007.

Golub LM, 2008. Use of non‑antibacterial tetracycline analogs for the treatment of bacterial exotoxins. U.S. Patent Application 2008/0233151, issued September 25, 2008.

Golub LM, 2008. Use of low‑dose chemically modified tetracyclines to reduce inflammatory mediators. U.S. Patent Application 2008/0249072, issued October 9, 2008.

Golub LM, 2010. Methods of reducing the risk of cardiovascular disease in postmenopausal women. WO Patent 2010/054015, issued May 14, 2010.

Golub LM, 2010. Curcumin analogues as zinc chelators and their uses. WO Patent 2010/132815, issued November 18, 2010.

Golub LM, 2012. Methods of reducing the risk of cardiovascular disease in postmenopausal women. U.S. Patent Application 2012/0046249, issued February 23, 2012.

Golub LM, 2013. Novel modified curcumins and their use. WO Patent 2013/059203, issued April 25, 2013.

Golub LM, 2014. Novel modified curcumins and their use. U.S. Patent Application 2014/0275271, issued September 18, 2014.

Golub LM, 2015. Chemically modified curcumins as inhibitors of anthrax lethal factor. U.S. Patent Application 2015/0073021, issued March 12, 2015.

Golub LM, 2015. Polyenolic zinc‑binding agents that promote inactivation of cancer stem cells and potentiate cytotoxic anti‑tumor drugs. U.S. Patent Application 2015/0150834, issued June 4, 2015.

Golub LM, 2017. Polyenolic zinc‑binding agents that promote inactivation of cancer stem cells and potentiate cytotoxic anti‑tumor drugs. U.S. Patent 9,675,576 B2, issued June 13, 2017.

Golub LM, 2018. Chemically modified curcumins for use in the production of lipoxins. U.S. Patent Application 2018/0036262, issued February 8, 2018.

Golub LM, 2020. Curcumin analogues as zinc chelators and their uses. U.S. Patent 11,669,227, issued June 2, 2020.

Golub LM, 2021. Chemically modified curcumins for use in the production of lipoxins. U.S. Patent Application 2021/0322346, issued October 21, 2021.

Golub LM, 2023. Curcumin analogues as zinc chelators and their uses. U.S. Patent 11,608,309, issued March 21, 2023.

NIH Merit Award (10 years funding 1988-98); University of Helsinki Rector's Medal (1991); Annual Birnberg Research Award, Columbia University (1996); Annual Distinguished Scientist Award in Oral Biology, IADR (1998); Ramfjord Memorial Lectureship, Univ. Michigan (1999); Faculty of Medicine, University Helsinki "Doctor Honoris Causa" (2000); Annual 'ADA Norton M. Ross Award for Excellence in Clinical Research (2001); Distinguished Alumnus Award University of Manitoba (Canada, 2002); "Outstanding Inventors Award", Research Foundation of SUNY (2002); promoted by the Board of Trustees, SUNY, to the rank of Distinguished Professor (2003); ADA Gold Medal for Excellence in Research (2006); Research highlighted in "Technology Transfer Stories- 25 Innovations that changed the world", Association University Technology Managers; DistinguishedFaculty Member, Center for Biotechnology (NYSTAR Center for Advanced Technology (2009); Invited to be guest editor of two special issues, Pharmacological Research, Elsevier Publishers, (2011); Research paper highlighted as Cover Story, JADA March (2011). Inducted member of Stony Brook University National Academy of Inventors (2016).